hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06370195, orgStudyIdInfo id: SGB-Liuxian, briefTitle: Effect of Stellate Ganglion Block on Drooling in Parkinson's Syndrome, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Babujinaya Cela, class: OTHER_GOV, descriptionModule briefSummary: This is a randomized controlled study, including dysphagic patients with Parkinson's syndrome who were received in the department of rehabilitation medicine. All patients are randomly allocated to the observation group or the control group. Both groups are provided with comprehensive rehabilitation. Besides, the observation group additionally undergoes the stellate ganglion block. At admission and after 10-day treatment, Functional Oral Intake Scale, Drooling amount, depression are assessed., conditionsModule conditions: Parkinson's Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Comprehensive rehabilitation, interventions name: Stellate ganglion block, interventions name: Lidocaine hydrochloride, interventions name: Placebo injection, outcomesModule primaryOutcomes measure: Drooling amount, secondaryOutcomes measure: Modified Barthel Index, secondaryOutcomes measure: Patient Health Questionnaire-9, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06370182, orgStudyIdInfo id: ANA2401, briefTitle: Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA5 Device, acronym: ATHENA, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Anaconda Biomed S.L., class: INDUSTRY, descriptionModule briefSummary: The objective of this study is to assess the safety and effectiveness of mechanical thrombectomy using the ANA funnel catheter to treat people with acute ischemic stroke within 24 hours of symptom onset. The device facilitates the placement of other devices such as stent retrievers and intravascular catheters during the procedure., conditionsModule conditions: Acute Ischemic Stroke From Large Vessel Occlusion, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule interventions name: ANA Funnel Catheter, interventions name: Control, outcomesModule primaryOutcomes measure: Proportion of subjects with "near-complete" reperfusion after one thrombectomy pass (FPE, eTICI 2c-3, extended Thrombolysis in Cerebral Infarction scale) in the target vessel after one reperfusion attempt., primaryOutcomes measure: Rate of symptomatic intracranial hemorrhage (sICH), attributable to the device or procedure., eligibilityModule sex: ALL, minimumAge: 22 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06370169, orgStudyIdInfo id: ROSC 1, briefTitle: EUS Guided Coil Embolization for Primary Prophylaxis of Gastric Varices, acronym: EUS, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-08-01, primaryCompletionDateStruct date: 2024-03-30, completionDateStruct date: 2024-08-10, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Asian Institute of Gastroenterology, India, class: OTHER, descriptionModule briefSummary: The standard treatment of bleeding gastric varices is obliteration with placement of coil and glue. Our study will evaluate the efficacy of EUS guided coil as primary prophylaxis for high-risk gastric varices. All procedures will be performed with patient under deep sedation or general anaesthesia under the supervision of an anaesthesiologist., conditionsModule conditions: Gastric Varices Bleeding, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Endoscopic ultrasound placement of Coil and glue, outcomesModule primaryOutcomes measure: The outcome will measure number of patient had achieved complete obliteration of varices, secondaryOutcomes measure: Number of patient needed re intervention, secondaryOutcomes measure: Number of patient needed had bleeding following intervention like immediate (with in 5 days) or later (5-90 days), eligibilityModule sex: ALL, minimumAge: 18 Months, maximumAge: 80 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Asian institute of Gastroenterology, status: RECRUITING, city: Hyderabad, state: Telangana, zip: 500082, country: India, contacts name: Jahangeer Dr Basha, MD DM, role: CONTACT, phone: 04023378888, email: drjahangeer09@gmail.com, contacts name: Sandeep Dr Nath, MD, role: CONTACT, phone: 04023378888, email: sandip.nath@ymail.com, geoPoint lat: 17.38405, lon: 78.45636, hasResults: False
protocolSection identificationModule nctId: NCT06370156, orgStudyIdInfo id: TWEAK in plaque psoriasis, briefTitle: Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-06-01, completionDateStruct date: 2025-06-10, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Egymedicalpedia, class: INDUSTRY, descriptionModule briefSummary: Psoriasis vulgaris is associated with significant comorbidity including depression, increased risk of cardiovascular events, diminished quality of life, as well as overall increased mortality.Moreover, concomitant psoriatic arthritis is present in up to 40% of psoriasis patients or will develop in the future.To enhance quality of life and potentially lower the risk of concomitant disease in psoriasis patients, effective treatment of this immune-mediated systemic inflammatory disease is required, conditionsModule conditions: Plaque Psoriasis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Adalimumab, outcomesModule primaryOutcomes measure: Treatment of psoriasis vulgaris and psoriatic arthritis, secondaryOutcomes measure: Evaluation of serum TWEAK, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: South Valley Hospitals, city: Qinā, country: Egypt, contacts name: Eisa Mohamed Hegazy, Professor, role: CONTACT, phone: +201094337795, email: eisa_mohamed4152@med.svu.edu.eg, geoPoint lat: 26.16418, lon: 32.72671, hasResults: False
protocolSection identificationModule nctId: NCT06370130, orgStudyIdInfo id: AerospaceCH, briefTitle: Different Dose of Esketamine Inhibiting Response to Laryngeal Mask Airway Insertion, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-05-01, primaryCompletionDateStruct date: 2022-12-20, completionDateStruct date: 2023-03-10, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Aerospace Center Hospital, class: OTHER, descriptionModule briefSummary: Objective To prospectively determine the median effective dose (ED50) of propofol for inhibiting a response to laryngeal mask airway (LMA) insertion when combined with different doses of esketamine in female patients.Methods Fifty-eight female patients (aged 20-60, ASAⅠ-Ⅱ) scheduled for elective hysteroscopy were enrolled and randomly divided into two groups, one administered 0.2 mg/kg of esketamine (K1 group, n = 28) and the other 0.3 mg/kg of esketamine (K2 group, n = 30). The two groups received the corresponding doses of esketamine intravenously, followed by an intravenous injection of propofol (injection time was 30 s). The initial dose of propofol was 2 mg/kg, and the dose ratio of propofol in the adjacent patients was 0.9. If there was a positive reaction to LMA insertion, the dose ratio in the next patient was increased by one gradient, and if not, the dose ratio was decreased by one gradient. The median effective dose (ED50), 95% effective dose (ED95) and 95% confidence interval (95%CI) of propofol for inhibiting a response to LMA insertion in the two esketamine groups were calculated using a probit analysis., conditionsModule conditions: Anesthesia, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 58, type: ACTUAL, armsInterventionsModule interventions name: Esketamine 0.2mg/kg, interventions name: Esketamine 0.3mg/kg, outcomesModule primaryOutcomes measure: Record of the patient response during LMA placement, primaryOutcomes measure: Overall condition of LMA placement, primaryOutcomes measure: Record related indicators, primaryOutcomes measure: Record related indicators, primaryOutcomes measure: Record related indicators, primaryOutcomes measure: Record related indicators, primaryOutcomes measure: Record of additional doses of propofol and the adverse reactions of positive patients during the induction process (hypotension, bradycardia and apnoea, etc.), eligibilityModule sex: FEMALE, minimumAge: 20 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Liang-Yuan Lu, city: Beijing, state: Beijing, zip: 100049, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06370117, orgStudyIdInfo id: Aydın Adnan Menderes, briefTitle: The Effects of Three Different Nonpharmacological Methods Used During Vascular Access in Children on Pain and Anxiety, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-02-01, primaryCompletionDateStruct date: 2023-10-30, completionDateStruct date: 2023-12-30, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Aydin Adnan Menderes University, class: OTHER, descriptionModule briefSummary: The research was conducted to evaluate the effects of three different non-pharmacological methods (playing a music video, buzzy application, listening to a music video + buzzy application) on the pain and anxiety levels of children in the 4-12 age group during vascular access.H0.1. Playing music (music video) during the vascular access procedure has no effect on children's pain and anxiety levels.H0.2. Applying buzzy during the vascular access procedure has no effect on children's pain and anxiety levels.H0.3. Listening to a music video + applying buzzy during the vascular access procedure has no effect on children's pain and anxiety levels., conditionsModule conditions: Pain, conditions: Anxiety, conditions: Nurse's Role, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: It is a randomized controlled experimental study., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 126, type: ACTUAL, armsInterventionsModule interventions name: Buzzy, interventions name: Music video listening, interventions name: Buzzy+ Music video listening, outcomesModule primaryOutcomes measure: Wong-Baker Facial Expression Rating Scale, secondaryOutcomes measure: Children's Fear and Anxiety Scale, eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Bircan Kahraman Berberoğlu, city: Aydın, state: AYDIN-efeler, zip: 0900, country: Turkey, geoPoint lat: 37.84501, lon: 27.83963, hasResults: False
protocolSection identificationModule nctId: NCT06370091, orgStudyIdInfo id: PICVII19-41, briefTitle: Effect of Xylitol-based Chewing Gums, Sugar-free and Sugared, on Salivary Flow and pH in Young Adults, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-12, primaryCompletionDateStruct date: 2024-05-31, completionDateStruct date: 2024-07-31, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Universidad Católica de Cuenca, class: OTHER, descriptionModule briefSummary: This study was planned to evaluate the effects of xylitol-based chewing gums, sugar-free and sugared, on salivary flow and pH in young adults., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: It will be an experimental study through a double-blind parallel randomized controlled trial.All saliva samples will be collected using the spitting method. Each participant will provide a basal saliva sample for 5 minutes. Participants must meet the following inclusion criteria: having at least 20 teeth, providing written informed consent, and being willing to comply with the study procedures. The exclusion criteria will include individuals with systemic, infectious, or inflammatory diseases or those taking medications, antibiotics, or fluoride in the last month; regular consumers of products and mouthwashes containing xylitol or sorbitol, with abnormal salivary flow (\<1 ml/min), pregnant women or those on contraceptive pill treatment, or with abnormal dietary habits; subjects with periodontal disease or presence of dental caries, primaryPurpose: OTHER, maskingInfo masking: DOUBLE, maskingDescription: Participants who meet the selection criteria will be probabilistically assigned using simple random sampling through a lottery system. An urn will be used to draw colors corresponding to a type of chewing gum, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Gum of Xylitol, interventions name: Gum of sugar free, interventions name: Gum of sugar, interventions name: Paraffin wax, outcomesModule primaryOutcomes measure: G1: Gum of xilytol, primaryOutcomes measure: G2: Gum of sugar free, primaryOutcomes measure: G3: Gum of sugar, primaryOutcomes measure: G4: Parafinn wax, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 25 Years, stdAges: ADULT, contactsLocationsModule locations facility: Miriam Lima, status: RECRUITING, city: Cuenca, state: Azuay, zip: 010101, country: Ecuador, contacts name: Miriam Lima, Ph D, role: CONTACT, phone: 0999975073, email: mlimai@ucacue.edu.ec, geoPoint lat: -2.90055, lon: -79.00453, documentSection largeDocumentModule largeDocs typeAbbrev: Prot, hasProtocol: True, hasSap: False, hasIcf: False, label: Study Protocol, date: 2023-12-12, uploadDate: 2024-04-13T10:26, filename: Prot_000.pdf, size: 1132158, hasResults: False
protocolSection identificationModule nctId: NCT06370078, orgStudyIdInfo id: Ahmed Helal, briefTitle: Effect of Early Administration of Albumin 20% Versus Crystalloid, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-11-01, completionDateStruct date: 2025-11-15, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Egymedicalpedia, class: INDUSTRY, descriptionModule briefSummary: Sepsis and septic shock are global health problems, leading to a high mortality rate. They are often associated with extremely low blood pressure and multiple organ dysfunctions, which are the main causes of death in critically ill patients. Fluid resuscitation is one of the most critical treatments for patients with sepsis and septic shock.An early administration of an appropriate fluid to patients is considered the most effective way to increase blood pressure, improve tissue perfusion, and save their lives. Crystalloid fluids are a subset of intravenous solutions composed of mineral salts and other small, water-soluble molecules, including normal, isotonic or hypertonic saline, and various buffered solutions., conditionsModule conditions: Septic Shock, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 46, type: ESTIMATED, armsInterventionsModule interventions name: Albumin Human, outcomesModule primaryOutcomes measure: Recovery from shock, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Assuit University hospitals, city: Assiut, country: Egypt, contacts name: Ahmed Abdelhamed Helal Mohamed, MSc, role: CONTACT, phone: +201140415513, email: Ahmedel3oksh@gmail.com, contacts name: Amany Hassan Abdelwahab, Assist.Prof., role: CONTACT, phone: +201004610623, email: Amanihassan1976@yahoo.com, contacts name: Noha Yahia Mohamed, Lecturer, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 27.18096, lon: 31.18368, hasResults: False
protocolSection identificationModule nctId: NCT06370065, orgStudyIdInfo id: HLX10IIT70-TJ, briefTitle: Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-04-27, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Tianjin Medical University Cancer Institute and Hospital, class: OTHER, descriptionModule briefSummary: Evaluation of the efficacy and safety of Serplulimab combined with bevacizumab biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) patients, conditionsModule conditions: Advanced Hepatocellular Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 35, type: ESTIMATED, armsInterventionsModule interventions name: HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04）, outcomesModule primaryOutcomes measure: ORR, secondaryOutcomes measure: PFS, secondaryOutcomes measure: OS, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tianjin Cancer Hospital Airport Hospital, status: RECRUITING, city: Tianjin, state: Tianjin, country: China, contacts name: Huikai Li, MD, role: CONTACT, geoPoint lat: 39.14222, lon: 117.17667, hasResults: False
protocolSection identificationModule nctId: NCT06370052, orgStudyIdInfo id: CHCRI-DJ-HS, briefTitle: Pathophysiological Basis of Hidradenitis Suppurativa, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Clinical Hospital Center Rijeka, class: OTHER, descriptionModule briefSummary: HS is a chronic inflammatory disease manifested by recurrent inflammatory nodules, abscesses and tunnels under the skin. This disease is characterized by an inflammatory process that takes place in hair follicles, sebaceous glands and surrounding tissue. Because of its frequent recurrence and chronicity, it represents a major public health problem and there is a need for better diagnosis and new and more effective drugs. This research can be a part of realizing the stated needs., conditionsModule conditions: Hidradenitis Suppurativa, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: excision, outcomesModule primaryOutcomes measure: The pathohistological changes, secondaryOutcomes measure: The expression of cytokines, secondaryOutcomes measure: The correlation of the clinical Hurley classification and pathohistological changes, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06370039, orgStudyIdInfo id: INV-102-CS-003, briefTitle: Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-27, primaryCompletionDateStruct date: 2024-08, completionDateStruct date: 2024-08, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Invirsa, Inc., class: INDUSTRY, descriptionModule briefSummary: Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during 4-week repeat dosing in subjects with moderate to severe dry eye disease., conditionsModule conditions: Dry Eye Disease, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 110, type: ESTIMATED, armsInterventionsModule interventions name: INV-102, interventions name: Vehicle, outcomesModule primaryOutcomes measure: Change from Baseline in corneal fluorescein staining total score on the National Eye Institute (NEI)/Industry scale, secondaryOutcomes measure: Percentage of eyes with complete clearing of central corneal fluorescein staining, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 74 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: iuvo BioScience, status: RECRUITING, city: Rush, state: New York, zip: 14543, country: United States, geoPoint lat: 42.9959, lon: -77.64556, hasResults: False